Orchid rumours: Aurobindo says reports inaccurate; Dr Reddy's won't comment on speculation

By Staff reporter

- Last updated on GMT

Orchid API plant in  Alathur, Chennai (source Orchid: Flickr)
Orchid API plant in Alathur, Chennai (source Orchid: Flickr)

Related tags: Dr reddy, Pharmacology

Aurobindo Pharma Limited has denied rumours it is interested in Orchid Pharma after a report suggested it is vying with Dr Reddy’s to acquire the bankrupt API firm.

The Indian drug manufacturer issued the statement today telling​ the Bombay stock Exchange (BSE) an Economic Times story ​ suggesting it is one of seven firms looking at Orchid is “factually incorrect.”

Dr Reddy's, which was mentioned as a potential suitor in the ET story, also responded​.

The firm said the reports are “purely speculative” adding that it is company policy not to comment on rumours.

The BSE asked Orchid for clarification after the Economic Times story.

In response​, Orchid said, “In terms of the provisions of insolvency and Bankruptcy Code (IBC) and regulations, the Resolution Professional has called for an expression of interest (EoI) for the submission of the resolution plan and the responses are under scrutiny​.”

The firm added: “The news item published in Economic Times date December 18,2017 referred to in your letter are not released by us​.”

Background

Investors started bankruptcy proceedings against Orchid on August 22​.

The following month​, India’s National Company Law Tribunal appointed an interim resolution professional​ (IRP) to manage the insolvency process.

In October​, a full time resolution professional (RP) was appointed and tasked with assessing all solutions to Orchid's financial woes, including seeking expressions of interest from companies interested in a takeover.

Assets

Orchid makes injectable drugs and active pharmaceutical ingredients (API) for the domestic and export markets.

The firm has ingredient plants in Alathur, Chennai and a finished dosage form site in nbeighbouring Irungattukottai.

According to its website – have all passed inspections by the US Food and Drug Administration (FDA) and the UK MHRA.

Related news

Show more

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers